# Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure

> **NCT01346215** · PHASE3 · UNKNOWN · sponsor: **Laboratório Químico Farmacêutico Bergamo Ltda.** · enrollment: 132 (estimated)

## Conditions studied

- Chronic Renal Failure

## Interventions

- **BIOLOGICAL:** heparin sodium
- **BIOLOGICAL:** heparin sodium

## Key facts

- **NCT ID:** NCT01346215
- **Lead sponsor:** Laboratório Químico Farmacêutico Bergamo Ltda.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-10
- **Primary completion:** 2011-12
- **Final completion:** 2012-02
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2011-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01346215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01346215, "Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01346215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*